RNA m<sup>6</sup> A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.
Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G. · 2020
Read RNA m<sup>6</sup> A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. by Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7298296.txt.
Description
Lin and co-authors uncover a chain by which liver cancer resists the drug sorafenib, involving an RNA-modifying enzyme. Their study appeared in The EMBO Journal. Hepatocellular carcinoma often stops responding to sorafenib, a standard therapy. The enzyme METTL3, which places the m6A chemical mark on RNA, turned out to be sharply reduced in resistant human tumors.
Lower METTL3, especially under low oxygen, promoted resistance and switched on blood-vessel growth genes and autophagy, the cell's recycling system. The key target was FOXO3: marking its RNA normally keeps it stable, with help from a reader protein. In patient samples, METTL3 and FOXO3 levels tracked together. In mouse tumors, losing METTL3 caused resistance, while restoring FOXO3 brought drug sensitivity back. The pathway offers new points of attack against resistant disease.
Catalog record
| CREATOR | Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |